The effects of sex steroids on colon carcinogenesis.

abstract：:The camptothecin derivative 9-nitrocamptothecin (9-NC) has demonstrated clinical activity in patients with ovarian and pancreatic carcinomas. Preclinical studies have shown promising activity of 9-NC for melanoma. We have thus conducted a phase II clinical trial of 9-NC for patients with metastatic cutaneous and uveal...

journal_title：Anti-cancer drugs

authors： Ellerhorst JA,Bedikian AY,Smith TM,Papadopoulos NE,Plager C,Eton O

更新日期：2002-02-01 00:00:00

abstract：:Methoxymorpholinyl doxorubicin (PNU 152243) is a morpholinyl analog possessing a methoxymorpholinyl group at the 3' position of the sugar moiety, which, compared with doxorubicin, appears to be less cardiotoxic and more cytotoxic against multidrug-resistant tumor cells. In this study, we report the anticancer activity...

journal_title：Anti-cancer drugs

authors： Yuan S,Zhang X,Lu L,Xu C,Yang W,Ding J

更新日期：2004-07-01 00:00:00

abstract：:The beta-carboline alkaloids are naturally existing plant substances. It is known that these alkaloids have a wide spectrum of neuropharmacological, psychopharmacological, and antitumor effects. Therefore, they have been traditionally used in oriental medicine for the treatment of various diseases including cancers an...

journal_title：Anti-cancer drugs

authors： Abe A,Yamada H

更新日期：2009-06-01 00:00:00

abstract：:Irinotecan (CPT-11) is a camptothecin analog with low (about 10--20%) and variable oral bioavailability in animal models. Here, Caco-2 cells were used to evaluate the transepithelial transport of CPT-11 and its metabolites. Caco-2 cells demonstrated significant expression of P-glycoprotein (P-gp), multidrug resistance...

journal_title：Anti-cancer drugs

authors： Yamamoto W,Verweij J,de Bruijn P,de Jonge MJ,Takano H,Nishiyama M,Kurihara M,Sparreboom A

更新日期：2001-06-01 00:00:00

abstract：:We chose to treat malignant pleural mesothelioma with a combination of docetaxel and irinotecan (CPT-11), because there have been preliminary reports that CPT-11 is active against mesothelioma, and docetaxel and CPT-11 were the most active agents in our in vitro experiments in human mesothelioma cell lines. Fifteen pr...

journal_title：Anti-cancer drugs

authors： Knuuttila A,Ollikainen T,Halme M,Mali P,Kivisaari L,Linnainmaa K,Jekunen A,Mattson K

更新日期：2000-04-01 00:00:00

abstract：:Patients with metastatic squamous cell cancer of the head and neck (SCCHN) have a poor prognosis, with most patients surviving less than a year. Immunotherapy (IO) is changing the natural history of the disease and programmed death-ligand 1 (PD-L1) inhibitors are showing notable improvements in survival with a more fa...

journal_title：Anti-cancer drugs

authors： Cabezas-Camarero S,Cabrera-Martín MN,Pérez-Segura P

更新日期：2019-02-01 00:00:00

abstract：:Linking chemotherapeutic drugs to a macromolecular carrier system may enhance tumor targeting, reduce toxicity and overcome drug resistance mechanisms. As an elementary model to evaluate the pharmacological properties of macromolecular drug carrier systems we chose rat serum albumin (RSA) for carrier and methotrexate ...

journal_title：Anti-cancer drugs

authors： Stehle G,Wunder A,Sinn H,Schrenk HH,Schütt S,Frei E,Hartung G,Maier-Borst W,Heene DL

更新日期：1997-10-01 00:00:00

abstract：:A patient with platinum resistant low-grade serous ovarian carcinoma had an objective response to therapy with bevacizumab and evidence of extended activity (>7 years). This case report adds to the growing literature regarding the use of bevacizumab in low-grade serous ovarian carcinoma. ...

journal_title：Anti-cancer drugs

authors： Rose PG,Roma A

更新日期：2013-10-01 00:00:00

abstract：:A phase II trial was performed to determine the efficacy and tolerance of docetaxel plus oxaliplatin with hematopoietic growth factor support in previously untreated patients with advanced gastroesophageal adenocarcinoma. Thirty-five patients were entered in this trial. Treatment consisted of 3-weekly docetaxel 80 mg/...

journal_title：Anti-cancer drugs

authors： Hejna M,Raderer M,Zacherl J,Ba-Ssalamah A,Püspök A,Schmidinger M,Pluschnig U,Brodowicz T,Zielinski CC

更新日期：2008-06-01 00:00:00

abstract：:The in vitro antitumor activity of navelbine (NVB, KW-2307), a newly synthesized vinca alkaloid, was compared with that of adriamycin (ADM) against human breast carcinomas inoculated into nude mice at the maximum tolerated dose (MTD) and clinically equivalent dose (CED). The plasma levels of NVB after intravenous inje...

journal_title：Anti-cancer drugs

authors： Tsuruo T,Inaba M,Tashiro T,Yamori T,Ohnishi Y,Ashizawa T,Sakai T,Kobayashi S,Gomi K

更新日期：1994-12-01 00:00:00

abstract：:In this study, we investigated the putative cytotoxic effect elicited by the garlic-derived compound S-allylcysteine (SAC) in two human cancer cell lines (HCC827 and NCI-H1975) in order to develop an experimental approach to the therapeutic potential of this molecule for lung cancer. Cells were incubated for 24, 48 an...

journal_title：Anti-cancer drugs

authors： Orozco-Morales M,Hernández-Pedro NY,Barrios-Bernal P,Arrieta O,Ruiz-Godoy LM,Aschner M,Santamaría A,Colín-González AL

更新日期：2021-02-01 00:00:00

abstract：:Response rates reported in early phase II clinical trials are often not reproduced in subsequent larger or phase III studies. Independent review of claimed partial or complete responders to gemcitabine was undertaken in four pivotal, open-label phase II studies of advanced, non-small cell lung cancer (NSCLC) to provid...

journal_title：Anti-cancer drugs

authors： Gwyther SJ,Aapro MS,Hatty SR,Postmus PE,Smith IE

更新日期：1999-09-01 00:00:00

abstract：:Magnesium wasting is a frequent side effect of epidermal growth factor receptor (EGFR)-antibody treatment as magnesium-absorption mechanisms are dependent on EGFR signaling. EGFR-inhibition results in decreased renal reabsorption. There is evidence that hypomagnesemia during cetuximab treatment correlates with respons...

journal_title：Anti-cancer drugs

authors： Schulz C,Heinemann V,Heinrich K,Haas M,Holch JW,Fraccaroli A,Held S,von Einem JC,Modest DP,Fischer von Weikersthal L,Kullmann F,Moehler M,Scheithauer W,Jung A,Stintzing S

更新日期：2020-09-01 00:00:00

abstract：:We evaluated the therapeutic activity and safety of continuously infused mitomycin C in patients with metastatic colorectal cancer who had recurred (less than 3 months) or progressed following first- or second-line 5-fluorouracil-based chemotherapy. Treatment consisted of mitomycin C 20 mg/m2 i.v. given over 120 h (5 ...

journal_title：Anti-cancer drugs

authors： Hartmann JT,Harstrick A,Daikeler T,Kollmannsberger C,Müller C,Seeber S,Kanz L,Bokemeyer C

更新日期：1998-06-01 00:00:00

abstract：:Salivary adenoid cystic carcinoma (SACC), which is one of the most common malignant tumors of the salivary glands, is associated with a poor long-term outcome. There are currently few therapeutic options for patients with SACC. Recent studies have shown the potential of the application of ultraviolet-C (UV-C) irradiat...

journal_title：Anti-cancer drugs

authors： Jiang Y,Ge XY,Liu SM,Zheng L,Huang MW,Shi Y,Fu J,Zhang JG,Li SL

更新日期：2014-10-01 00:00:00

abstract：:The prevalence of chronic myeloid leukemia and multiple myeloma has increased in recent years partly because of an improved therapeutic armamentarium for both conditions. Likewise, understanding the complexity inherent in designing combination treatment strategies will become increasingly prescient in the coming years...

journal_title：Anti-cancer drugs

authors： Katzel JA,Lee-Ma A,Vesole DH

更新日期：2015-09-01 00:00:00

abstract：:In melanoma, the RAS/RAF/MEK/ERK pathway is frequently activated by mutations in BRAF and NRAS. Selumetinib (AZD6244) is an oral, selective, non-ATP-competitive inhibitor of MEK1/2. Here, we describe a patient with metastatic melanoma (T1N2cM1a) with a BRAF V600E mutation. She is currently being treated with selumetin...

journal_title：Anti-cancer drugs

authors： Boers-Sonderen MJ,Desar IM,Blokx W,Timmer-Bonte JN,van Herpen CM

更新日期：2012-08-01 00:00:00

abstract：:In the APHINITY study (NCT01358877, BIG 4-11/BO25126/TOC4939G), pertuzumab added to trastuzumab and chemotherapy significantly improved invasive disease-free survival as adjuvant treatment for patients with HER2-positive early breast cancer. The objective of this analysis was to assess the pharmacokinetics of pertuzum...

journal_title：Anti-cancer drugs

authors： Luo Y,Li W,Jiang Z,Zhang Q,Wang L,Mao Y,Tjan-Heijnen VCG,Im SA,McConnell R,Bejarano S,Fumagalli D,Bines J,Wang B,Garg A,Kirschbrown WP,Xu B

更新日期：2019-09-01 00:00:00

abstract：:Trifluorothymidine (TFT) is a fluorinated thymidine analog that after conversion to its monophosphate derivative can inhibit thymidylate synthase (TS) and be incorporated into DNA. TFT is a good substrate for thymidine phosphorylase (TP), and the combination of TFT and a TP inhibitor (TPI), called TAS-102, has been de...

journal_title：Anti-cancer drugs

authors： Temmink OH,de Bruin M,Comijn EM,Fukushima M,Peters GJ

更新日期：2005-03-01 00:00:00

abstract：:Clinical empiricism has recognized resistant breast cancer as a privileged target for docetaxel (Taxotere). This worldwide registration will offer medical oncologists the opportunity to develop new indications for docetaxel. Pharmacokinetics, preclinical optimal combination and clinical practice will constitute the ra...

journal_title：Anti-cancer drugs

authors： Armand JP

更新日期：1996-08-01 00:00:00

abstract：:Five hundred and fifty thousand new head and neck cancer cases are diagnosed each year worldwide. They are mostly locally advanced squamous cell carcinoma with a poor prognosis in terms of locoregional and distant failure. A major challenge for patients with locally advanced squamous cell carcinoma is to achieve a hig...

journal_title：Anti-cancer drugs

authors： Pointreau Y,Atean I,Fayette J,Calais G,Lefebvre JL

更新日期：2011-08-01 00:00:00

abstract：:Cantharidin is a natural toxin that possesses potent anti-tumor properties. Its clinical application, however, is limited due to severe side-effects. Its cytotoxicity is believed to be mediated by the inhibition of serine/threonine protein phosphatase 2A. In order to identify new compounds with potential clinical ther...

journal_title：Anti-cancer drugs

authors： Shan HB,Cai YC,Liu Y,Zeng WN,Chen HX,Fan BT,Liu XH,Xu ZL,Wang B,Xian LJ

更新日期：2006-09-01 00:00:00

abstract：:Intensive cisplatin and oral etoposide for relapsed epithelial ovarian cancer (EOC), commonly known as the van der Burg (VDB) protocol, has been reported to improve response rates and progression-free survival. We report on all patients with relapsed EOC treated on the VDB protocol at the Cambridge Gynae-Oncology Cent...

journal_title：Anti-cancer drugs

authors： Gounaris I,Iddawela M,Parkinson C,Pratt J,Hatcher H,Basu B,Tan LT,Brenton JD,Earl HM

更新日期：2016-03-01 00:00:00

abstract：:The goal of this study was to identify clinical characteristics and concurrent medications associated with an increased or decreased incidence of cisplatin-induced nephrotoxicity. The medical records for 62 subjects with head and neck cancer who received cisplatin 100 mg/m2 (day 1) plus fluorouracil 1000 mg/m2 (days 1...

journal_title：Anti-cancer drugs

authors： Shord SS,Thompson DM,Krempl GA,Hanigan MH

更新日期：2006-02-01 00:00:00

abstract：:ET-743 is a marine anti-cancer drug and is currently in phase I trials in which the effect of combination therapies will be investigated. Its dose-limiting toxicity in patients is hepatotoxicity. In-vitro studies have shown that ET-743 is mainly metabolized by cytochrome P450 (CYP) 3A4, but also by 2C9, 2C19, 2D6 and ...

journal_title：Anti-cancer drugs

authors： Brandon EF,Meijerman I,Klijn JS,den Arend D,Sparidans RW,Lázaro LL,Beijnen JH,Schellens JH

更新日期：2005-10-01 00:00:00

abstract：:Our objective was to clarify the efficacy of UFT administration after the complete resection of non-small cell lung cancer (NSCLC) at a single-center institution, avoiding the biases produced by interinstitutional differences. A total of 30 patients who underwent the complete resection of NSCLC at our hospital between...

journal_title：Anti-cancer drugs

authors： Ueda H,Sakada T,Kuwahara M,Motohiro A

更新日期：2004-01-01 00:00:00

abstract：:To investigate the effectiveness of EDL-291, a 6,7-dimethoxy-1-[4-(4-methoxypyridin-3-yl)benzyl]-1,2,3,4-tetrahydroisoquinoline dihydrochloride compound, in inhibiting the survival of glioblastoma in vitro and in vivo. Dose-response curves were generated to determine the EC50 in rat and human glioblastoma cell lines b...

journal_title：Anti-cancer drugs

authors： Wang XD,Freeman NE,Patil R,Patil SA,Mitra S,Orr WE,Abner CW,Yates CR,Miller DD,Geisert EE

更新日期：2012-06-01 00:00:00

abstract：:C-reactive protein (CRP) is an independent prognostic factor for renal cell carcinoma (RCC). The aim of the present study was to investigate the overall prognostic impact of CRP in patients with metastatic RCC treated with sorafenib. Between April 2008 and December 2014, 40 consecutive patients with metastatic RCC wer...

journal_title：Anti-cancer drugs

authors： Fujita T,Nishi M,Tabata K,Matsumoto K,Yoshida K,Iwamura M

更新日期：2016-11-01 00:00:00

abstract：:The purpose of the current study was to develop and test a theoretical model that could explain the mechanism of action of gallic acid (GA) in the oral squamous cell carcinoma context for the first time. The theoretical model was developed using bioinformatics and interaction network analysis to evaluate the effect of...

journal_title：Anti-cancer drugs

authors： Guimaraes TA,Farias LC,Fraga CA,Feltenberger JD,Melo GA,Coletta RD,Souza Santos SH,de Paula AM,Guimaraes AL

更新日期：2016-06-01 00:00:00

abstract：:A combined treatment with conventional chemotherapies can enhance the effectiveness of chemotherapeutic agents against cancers. Here, we have shown that the naturally occurring triterpenoids synergistically enhance the response of cervical cancer cells to taxol. Of the triterpenoid compounds, pristimerin enhanced the ...

journal_title：Anti-cancer drugs

authors： Eum DY,Byun JY,Yoon CH,Seo WD,Park KH,Lee JH,Chung HY,An S,Suh Y,Kim MJ,Lee SJ

更新日期：2011-09-01 00:00:00